CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Testosterone Enanthate +2 moredrug
Likely dose
Testosterone Enanthate 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00475501
NCT00475501Phase 2Completed
CompareCT.gov

5-Alpha Reductase and Anabolic Effects of Testosterone

VA Office of Research and Development·interventional·Posted May 21, 2007·Updated Oct 11, 2018

In Brief

A Phase 2 clinical trial evaluating Testosterone Enanthate, Finasteride, and 1 other intervention for Male Hypogonadism and 3 related conditions. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether a higher-than-replacement dose of testosterone and finasteride can be combined to safely increase muscle strength in older men who have a low blood concentration of testosterone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMale Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy
CountriesUnited States
CollaboratorsEndo Pharmaceuticals, Merck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 21, 2007
Enrollment StartJan 1, 2007
Primary CompletionMar 1, 2012
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 19.1 years ago

Interventions

Testosterone Enanthatedrug

125 mg, i.m. injection, once/week, for 52 weeks

Finasteridedrug

5 mg, oral, once/day, for 52 weeks

Placeboother

Placebo